Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-25-006313
Filing Date
2025-01-16
Accepted
2025-01-16 18:33:29
Documents
7

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 13425
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 70899
3 EX-99.2 ck0001669811-ex99_2.pdf EX-99.2 121697
4 EX-99.3 ck0001669811-ex99_3.pdf EX-99.3 122017
5 EX-99.4 ck0001669811-ex99_4.pdf EX-99.4 121071
6 EX-99.5 ck0001669811-ex99_5.pdf EX-99.5 121690
7 EX-99.6 ck0001669811-ex99_6.pdf EX-99.6 501584
  Complete submission text file 0000950170-25-006313.txt   1474900
Mailing Address MCCARTHY LEGAL SERVICES 1188 CENTRE STREET NEWTON CENTRE MA 02459
Business Address MCCARTHY LEGAL SERVICES 1188 CENTRE STREET NEWTON CENTRE MA 02459 617-244-2800
Morningside Venture Investments Ltd (Filed by) CIK: 0001543112 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Subject) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-90539 | Film No.: 25536649
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)